Disease Information

General Information of the Disease (ID: DIS00373)

• Name: Essential thrombocythemia
• ICD: ICD-11: 3B63

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Clinical Trial Drug(s) 1 drug(s) in total

BMS-911543

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Tyrosine-protein kinase JAK2 (JAK3) [1]

• Sensitive Disease: Essential thrombocythemia [ICD-11: 3B63.Z]
• Molecule Alteration: Missense mutation; p.V617F (c.1849G>T)
• Sensitive Drug: BMS-911543
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: [3H] thymidine incorporation assay
• Mechanism Description: The missense mutation p.V617F (c.1849G>T) in gene JAK2 cause the sensitivity of BMS-911543 by aberration of the drug's therapeutic target

References

• Ref 1: Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2Leukemia. 2012 Feb;26(2):280-8. doi: 10.1038/leu.2011.292. Epub 2011 Oct 21.